V Wealth Advisors’s Cytokinetics CYTK Stock Holding History

V Wealth Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-500	Closed	-$6K	–	304
2017 Q2	$6K	Buy	+500	New	+$6.95K	﹤0.01%	632

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LPU

Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

V Wealth Advisors's CYTK Position: Q3 2017 in Review

V Wealth Advisors sold out of Cytokinetics (CYTK) in Q3 2017, closing a stake of 500 shares — an estimated $6K sold.

V Wealth Advisors first reported a position in CYTK in Q2 2017 and held it in 1 quarter. The position peaked at $6K in Q2 2017. 132 funds tracked by Wall St. Rank hold CYTK as of Q3 2017.

V Wealth Advisors reported no remaining Cytokinetics position as of Q3 2017 after selling out during the quarter.
V Wealth Advisors sold 500 Cytokinetics shares in Q3 2017, an estimated $6K.
V Wealth Advisors first reported a position in Cytokinetics in Q2 2017 and held it in 1 quarter.
V Wealth Advisors's Cytokinetics position peaked at $6K in Q2 2017.
132 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2017.

Based on V Wealth Advisors's 13F filing for Q3 2017, filed 12 Oct 2017.